Can a Triple-Drug combo erase rectal tumors before surgery?

NCT ID NCT07750951

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This phase II trial is testing whether giving a combination of two immunotherapies (sintilimab and IBI-310) along with chemotherapy before surgery can improve outcomes for people with a specific type of locally advanced rectal cancer (MSI-H/dMMR). The main goal is to see how often the tumor completely disappears after this pre-surgical treatment. The study will also look at side effects, whether surgery can be less invasive, and long-term survival. About 34 adults with this cancer type will receive the drug combination for six weeks, followed by surgery or close monitoring depending on how well the tumor responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination of three drugs: sintilimab (an immunotherapy that helps the immune system attack cancer), IBI-310 (another immunotherapy that boosts immune response), and chemotherapy (capecitabine and oxaliplatin).
What this could lead to
If successful, this approach could shrink or eliminate rectal tumors before surgery, potentially allowing some patients to avoid major surgery or preserve their sphincter, improving quality of life.
What could go wrong
This is a small, early-phase study (34 participants), so results may not apply broadly. Immunotherapy and chemotherapy can cause significant side effects, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MSI-H/DMMR LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital,the Air Force Medical University

    RECRUITING

    Xi'an, Shaanxi, 710032, China